The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

May 11, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Baricitinib for COVID-19?
On April 10, Eli Lilly, the manufacturer of baricitinib (Olumiant), announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to study baricitinib as an arm of the agency’s Adaptive COVID-19 Treatment Trial.1

You Might Also Like
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
  • FDA Approves Baricitinib for RA Patients
Explore This Issue
June 2020
Also By This Author
  • New Gabapentinoid Warning Labels

Baricitinib is an oral JAK1/JAK2 inhibitor approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor antagonists. The hypothesis is that the inflammatory cascade seen in patients with COVID-19 may be lessened by baricitinib’s anti-inflammatory activity.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study, which began in April, will investigate the safety and efficacy of baricitinib as a potential treatment for hospitalized patients with COVID-19. As this is being written, researchers have not yet started recruiting patients in the U.S. (ClinicalTrials.gov Identifier: NCT04373044). The trial has a planned expansion to sites in Europe and Asia. Results are expected in coming months.

Baricitinib’s U.S. prescribing information includes FDA boxed warnings regarding the risk of developing serious infections, possibly related to baricitinib’s effects on the immune system.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ranitidine Removed from U.S. Market
On April 1, the FDA issued a request to all manufacturers of ranitidine (sold under the trade name Zantac and others) to immediately withdraw all over-the-counter (OTC) and prescription ranitidine products from the U.S. market. The histamine-2 blocker, which decreases acid, is used to treat and prevent stomach and intestinal ulcers, as well as to treat gastroesophageal reflux disease.2

This decision is the last step in an ongoing FDA investigation into a probable carcinogenic contaminant, N-nitrosodimethylamine (NDMA), found in some ranitidine products. NDMA is an impurity that increases in amount over time and when the product is stored at or exposed to greater than room temperatures.

After the product withdrawal is complete, ranitidine will not be available for new or existing prescriptions or OTC use in the U.S. Patients taking prescription ranitidine should speak with their healthcare providers about other available treatments before stopping ranitidine. Other drugs in the same class do not have the same NDMA risks. To date, the FDA’s testing has not found NDMA in cimetidine, esomeprazole, famotidine, lansoprazole or omeprazole.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Eli Lilly and Company. News release: Lilly begins clinical testing of therapies for COVID-19. 2020 Apr 10.
  2. U.S. Food and Drug Administration. News release: All ranitidine products (Zantac): Press Release—FDA requests removal. 2020 Apr April 1.

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Safety Tagged With: baricitinib, COVID-19, Drug Safety, ranitidine, U.S. Food and Drug Administration (FDA)Issue: June 2020

You Might Also Like:
  • Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
  • FDA Approves Baricitinib for RA Patients
  • Lilly’s Lupus Treatment Succeeds in Mid-Stage Trial

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)